Back to top
more

Dyne Therapeutics (DYN)

(Delayed Data from NSDQ)

$25.46 USD

25.46
807,667

+0.91 (3.71%)

Updated Apr 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics

by Zacks Equity Research

Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Stocks to Buy as the Drug Industry Bets Big on Innovation

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.

All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy

by Zacks Equity Research

Dyne Therapeutics, Inc. (DYN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 84% in Dyne Therapeutics, Inc. (DYN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Dyne Therapeutics, Inc. (DYN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Wall Street Analysts Predict a 141% Upside in Dyne Therapeutics, Inc. (DYN): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Dyne Therapeutics, Inc. (DYN) points to a 141% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Best Momentum Stocks to Buy for July 18th

by Zacks Equity Research

DINO, DYN, and DLNG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 18, 2022.

Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate

by Zacks Equity Research

Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.

Vistra Energy (VST) Surges: Stock Moves 5.8% Higher

by Zacks Equity Research

The shares of Vistra Energy (VST) rose after the company announced that it has completed the previously announced merger with Dynegy.

    Zacks.com featured highlights include: Weight Watchers, Match, Dynegy and HFF

    by Zacks Equity Research

    Zacks.com featured highlights include: Weight Watchers, Match, Dynegy and HFF

      4 Hot Momentum Stocks for Impressive Returns

      by Zacks Equity Research

      This screen will help you to get into momentum stocks that are storming ahead. Highlighted stocks include WTW, MTCH and HF.

        Nalak Das headshot

        Robust Private Sector Hiring in March: 5 Top-Ranked Picks

        by Nalak Das

        Strong business sentiments together with business-friendly policies and solid earnings should pave the way for a bull run in the second quarter of 2018.

          DTE Energy (DTE) to Raise Generation Capacity in Michigan

          by Zacks Equity Research

          DTE Energy's (DTE) Renewable Energy Plan has provisions for installing approximately 15 MW of new Michigan-based solar capacity over the next three years.

            Tirthankar Chakraborty headshot

            New Strong Buy Stocks for April 3rd

            by Tirthankar Chakraborty

            Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

              Eversource's Capital Project & Acquisitions to Drive Growth

              by Zacks Equity Research

              Eversource Energy (ES) is poised to benefit from investments made to strengthen its infrastructure. Acquisition of water assets is going to further expand its revenue base.

                Tirthankar Chakraborty headshot

                New Strong Buy Stocks for March 16th

                by Tirthankar Chakraborty

                Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

                  Dynegy (DYN) Scales a 52-Week High on Asset Divestitures

                  by Zacks Equity Research

                  Dynegy (DYN) hits a 52-week high on the back of divestitures and strategic acquisition of gas-based production assets.

                    Options Traders Expect Huge Moves in Dynegy (DYN) Stock

                    by Zacks Equity Research

                    Investors in Dynegy (DYN) need to pay close attention to the stock based on moves in the options market lately.

                      Tax Reforms to Benefit Southern Company's (SO) Customers

                      by Zacks Equity Research

                      U.S. tax reform is going to result in generating savings of around $1.2 billion for Southern Company's (SO) subsidiary, Georgia Power's customers.

                        Will Higher Revenues Drive Interpublic's (IPG) Q4 Earnings?

                        by Zacks Equity Research

                        The Interpublic Group of Companies (IPG) is likely to record higher revenues in fourth quarter on the back of its strong digital capabilities, diversified business model and strategic acquisitions.

                          Republic Services' (RSG) Collection Unit to Aid Q4 Earnings?

                          by Zacks Equity Research

                          Focus on increasing operational efficiency and structural realignment of operations are likely to drive Republic Services' (RSG) Q4 earnings.

                            Brookfield Infrastructure (BIP) Q4 Earnings: What's in Store?

                            by Zacks Equity Research

                            Brookfield Infrastructure Partners (BIP) is likely to benefit from its expanding rate base, which will get reflected in its Q4 earnings, set to be released on Feb 9.

                              Will Rate Hikes Help Exelon (EXC) to Beat Earnings in Q4?

                              by Zacks Equity Research

                              Exelon Corporation (EXC) is expected to beat earnings expectations in fourth quarter thanks to new rates and its ongoing investments to strengthen infrastructure.

                                Dynegy Sells Massachusetts Coal Facility, Merger in Progress

                                by Zacks Equity Research

                                Dynegy Inc. (DYN) sells retired coal-fueled unit in Massachusetts for economic and social benefit of the community. Additionally, its merger with Vistra Energy is in progress.

                                  Company News For Oct 31, 2017

                                  by Zacks Equity Research

                                  Companies in the news are: DYN, AKZA, L, CNA